SCHEMBL49918

SCHEMBL49918

C[N][Si](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
GLA P06280 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CA14 Q9ULX7 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
ALOX12 P18054 1/20 0.33
ACHE P22303 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146838 0.75 ESR1 (0.40) ESR1ESR2CA12CA1CA2
SCHEMBL49706 0.69 ALDH1A1 (0.43) ESR1ESR2CA12CA1CA2
SCHEMBL1416688 0.69 ESR1 (0.36) ESR1ESR2CA12CA1CA2
SCHEMBL13380154 0.67 ESR1 (0.44) ESR1ESR2CA4LMNATSHR
SCHEMBL8967403 0.67 ESR1 (0.44) ESR1ESR2CA12CA2CA3
SCHEMBL2786417 0.65 ESR1 (0.33) ESR1ESR2
SCHEMBL27683515 0.65 ESR1 (0.33) ESR1ESR2
SCHEMBL3275968 0.65 ESR1 (0.33) ESR1ESR2
SCHEMBL63526 0.65 ESR1 (0.70) ESR1ESR2CA4LMNATSHR
SCHEMBL439492 0.65 ESR1 (0.48) ESR1ESR2CA4LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004414-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2010-01-07 US claimed
US-9469710-B2 Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2016-10-18 US disclosed
US-9403919-B2 Polymers functionalized with a carboxylic or thiocarboxylic ester containing a silylated amino group BRIDGESTONE CORPORATION (JP) 2016-08-02 US disclosed
EP-2751142-B1 POLYMERS FUNCTIONALIZED WITH LACTONES OR THIOLACTONES CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORP (JP) 2015-12-09 EP disclosed
US-20150148489-A1 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2015-05-28 US disclosed
US-8993683-B2 Polymers functionalized with lactones or thiolactones containing a protected amino group BRIDGESTONE CORPORATION (JP) 2015-03-31 US disclosed
US-8962745-B2 Functionalized polymers and vulcanizates with reduced hysteretic loss BRIDGESTONE CORPORATION (JP) 2015-02-24 US disclosed
US-8895670-B2 Functionalized polymers and methods for their manufacture BRIDGESTONE CORPORATION (JP) 2014-11-25 US disclosed
US-8735494-B2 Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2014-05-27 US disclosed
EP-2483317-B1 FUNCTIONALIZED POLYMERS AND METHODS FOR THEIR MANUFACTURE BRIDGESTONE CORP (JP) 2014-02-26 EP disclosed
US-20120165464-A1 FUNCTIONALIZED POLYMERS AND VULCANIZATES WITH REDUCED HYSTERETIC LOSS BRIDGESTONE CORPORATION (JP) 2012-06-28 US disclosed
US-20120059112-A1 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS COMTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2012-03-08 US disclosed
US-8129467-B2 Curing accelerating compound-silica composite material, method for producing curing accelerating compound-silica composite material, curing accelerator, curable resin composition, and electronic component device HITACHI CHEMICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-8013052-B2 Curable resin, production method thereof, epoxy resin composition, and electronic device HITACHI CHEMICAL COMPANY, LTD. (JP) 2011-09-06 US disclosed
US-20110144282-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2011-06-16 US disclosed
US-20110077325-A1 FUNCTIONALIZED POLYMERS AND METHODS FOR THEIR MANUFACTURE BRIDGESTONE CORPORATION (JP) 2011-03-31 US disclosed
US-7906592-B2 Polymers functionalized with imide compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2011-03-15 US disclosed
US-20100004414-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2010-01-07 US disclosed
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE HITACHI CHEMICAL CO., LTD. (JP) 2009-03-05 US disclosed
US-20090023855-A1 NOVEL CURABLE RESIN, PRODUCTION METHOD THEREOF, EPOXY RESIN COMPOSITION, AND ELECTRONIC DEVICE RESONAC CORPORATION (JP) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144282-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP PARG, PIN1, NPEPPS ESR1 3255/4885ESR2 4131/4885CA12 2942/4885
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE NCAPH, RAD51, H1-2 ESR1 433/4885ESR2 762/4885CA12 2683/4885
US-20100004414-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP PARG, PIN1, NPEPPS ESR1 3255/4885ESR2 4131/4885CA12 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.